Vanda Pharmaceuticals (VNDA) Net Income Growth (3y) (2013 - 2026)

Vanda Pharmaceuticals (VNDA) Net Income Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 9.16%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 38.43%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 13.80%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -3.84%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 79.26%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Vanda Pharmaceuticals 310.98 Mn 108.67 Mn 48.56 Mn -157.29%

Historic Data

Download Data
DateValue
Mar 31, 2026 -157.29%
Dec 31, 2025 -182.64%
Sep 30, 2025 -107.45%
Jun 30, 2025 -132.06%
Mar 31, 2025 -65.86%
Dec 31, 2024 -39.06%
Sep 30, 2024 -39.11%
Jun 30, 2024 -35.14%
Mar 31, 2024 -35.35%
Dec 31, 2023 -31.84%
Sep 30, 2023 -71.55%
Jun 30, 2023 -44.42%
Mar 31, 2023 87.97%
Dec 31, 2022 17.45%
Sep 30, 2022 -68.09%
Jun 30, 2022 -39.20%
Mar 31, 2022 -119.41%
Dec 31, 2021 -11.98%
Sep 30, 2021 2.50%
Jun 30, 2021 27.93%